This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Joseph Wasselle, MD; Jeanne Becker, PhD; C. Wayne Cruse, MD; Carmen Espinosa, MD; Charles Cox, MD; Douglas Reintgen, MD

Arch Surg. 1991;126(4):481-484.

Abstract
• Finding a screening test to evaluate patients with cancer for occult metastatic disease, as well as imaging all known disease, is a goal of research efforts. Twenty-nine evaluable patients with deeply invasive (stage I), regional nodal (stage II), or systemic (stage III) melanoma underwent imaging by administration of a preparation of the antimelanoma antibody labeled with technetium 99m. Scan results indicated that 28 of 32 confirmed metastatic sites were imaged with this technique (88% sensitivity). Analysis of the individual positive sites revealed that nodal basins and visceral metastases accounted for the highest percentage of metastatic sites imaged, with 14 (88%) of 16 nodal basin metastases and all four visceral metastases being detected through imaging. Occult nodal disease was detected in the iliac nodal chain in two of the 29 patients. The imaging of benign tumors and nodal basins not containing disease accounted for a confirmed false-positive rate of 21%. Three (10%) of the 29 scan results were confirmed to be false-negative. In vivo tumor localization with monoclonal antibodies showed a sensitivity similar to that of other roentgenographic procedures for identifying metastatic disease and was useful in two of three patients in identifying occult iliac nodal disease, a region that is difficult to evaluate with physical examination and other imaging modalities.

(Arch Surg. 1991;126:481-484)

Author Affiliations
From the Departments of Surgery (Drs Wasselle, Becker, Cruse, Cox, and Reintgen) and Pathology (Dr Espinosa), Melanoma Treatment Center, University of South Florida, Tampa.

Footnotes
Accepted for publication January 12, 1991.

Read before the 43rd Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, May 20, 1990.

Reprint requests to the H. Lee Moffitt Cancer Center, University of South Florida, PO Box 280179, Tampa, FL 33682-0179 (Dr Reintgen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?